BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Feb. 14, 2011
View Archived Issues
Targacept begins phase II trials of TC-6987 in asthma and type 2 diabetes
Read More
IntelGenx's INT-0022 shows bioequivalence to a leading antipsychotic
Read More
Gilead resubmits NDA for single-tablet Truvada/TMC-278 regimen in HIV-1
Read More
Protein S100-A12 levels correlate with pathological activity in Behcet's disease / News in Context
Read More
Botulinum neurotoxin type A is efficacious in urological disorders
Read More
PF-04605412 displays marked antitumor effects in vivo
Read More
Dentin matrix acidic phosphoprotein 1 plays a role in angiogenesis
Read More
Mallinckrodt describes new prodrugs of hydromorphone
Read More
New deuterated 2,4-pyrimidinediamines claimed for autoimmune diseases
Read More
New urotensin UT receptor antagonists divulged
Read More
Taisho Pharma patents new inhibitors of GlyT1
Read More
Sareum provides update on Aurora+FLT3 kinase program
Read More
Promedior begins phase Ib PRM-151 trial in idiopathic pulmonary fibrosis
Read More
Theravance identifies novel inhibitors of NET and 5HTT
Read More
Neuralstem provides update on stem cell study for ALS
Read More
INX-08189 receives FDA fast track status in chronic hepatitis C
Read More
Intellikine and PKD Foundation collaborate on treatment of polycystic kidney disease
Read More
Genta begins tesetaxel trial in advanced prostate cancer
Read More
Candesartan heart failure therapy is associated with lower all-cause mortality than losartan
Read More
Alexion acquires investigational therapy for molybdenum cofactor deficiency
Read More
Zogenix completes enrollment in phase III efficacy trial of ZX-002
Read More
Renovo's phase III REVISE trial of Juvista does not meet primary or secondary endpoints
Read More
Medivir and Janssen enter R&D collaboration for dengue virus infection
Read More
Eisai and Teikoku Seiyaku enter license agreement for transdermal Aricept in Japan
Read More
BioSante to continue enrollment in phase III LibiGel program following safety review
Read More